Telehealth startup Cerebral adjusted its marketing and advertising strategies to reflect the suspension of controlled substance prescriptions for new patients after allegations of overprescribing by providers surfaced, M+MM reported May 10.
Read the full post on Becker's Hospital Review - Healthcare News
